★ WIDE MOAT STOCKS COMPARISON ★

Checking

Stock Comparison

Elekta AB (publ) vs Pro Medicus Limited

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

Elekta AB (publ)

EKTA B · NASDAQ Stockholm

Market cap (USD)$2.1B
Gross margin (TTM)37.4%
Operating margin (TTM)5.3%
Net margin (TTM)-3.1%
SectorHealthcare
IndustryMedical - Instruments & Supplies
CountrySE
Data as of2026-06-03
Moat score
70/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Elekta AB (publ)'s moat claims, evidence, and risks.

View EKTA B analysis

Pro Medicus Limited

PME · ASX

Market cap (USD)$9.7B
Gross margin (TTM)78.3%
Operating margin (TTM)73.3%
Net margin (TTM)78.3%
SectorHealthcare
IndustryMedical - Healthcare Information Services
CountryAU
Data as of2026-06-02
Moat score
83/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Pro Medicus Limited's moat claims, evidence, and risks.

View PME analysis

Comparison highlights

  • Moat score gap: Pro Medicus Limited leads (83 / 100 vs 70 / 100 for Elekta AB (publ)).
  • Segment focus: Elekta AB (publ) has 2 segments (55.8% in Solutions); Pro Medicus Limited has 2 segments (92.5% in Visage 7 Enterprise Imaging Platform (PACS / CloudPACS)).
  • Primary market structure: Oligopoly vs Oligopoly. Pricing power: Moderate vs Strong.
  • Moat breadth: Elekta AB (publ) has 7 moat types across 3 domains; Pro Medicus Limited has 6 across 2.

Primary market context

Elekta AB (publ)

Solutions

Market

Radiotherapy treatment delivery systems and oncology software solutions (linacs, MR-Linacs, stereotactic radiosurgery, treatment planning & oncology information systems)

Geography

Global

Customer

Hospitals, cancer centers, and clinics (often via public/central procurement)

Role

Medical device OEM + software/platform provider

Revenue share

55.8%

Pro Medicus Limited

Visage 7 Enterprise Imaging Platform (PACS / CloudPACS)

Market

Enterprise imaging / PACS and related modules for hospitals and integrated delivery networks (IDNs)

Geography

Primarily North America; also Europe and Australia

Customer

Hospitals, imaging centers, integrated delivery networks (IDNs)

Role

Healthcare IT software vendor / platform provider

Revenue share

92.5%

Side-by-side metrics

Elekta AB (publ)
Pro Medicus Limited
Ticker / Exchange
EKTA B - NASDAQ Stockholm
PME - ASX
Market cap (USD)
$2.1B
$9.7B
Gross margin (TTM)
37.4%
78.3%
Operating margin (TTM)
5.3%
73.3%
Net margin (TTM)
-3.1%
78.3%
Sector
Healthcare
Healthcare
Industry
Medical - Instruments & Supplies
Medical - Healthcare Information Services
HQ country
SE
AU
Primary segment
Solutions
Visage 7 Enterprise Imaging Platform (PACS / CloudPACS)
Market structure
Oligopoly
Oligopoly
Market share
40%-44% (reported)
55% (implied)
HHI estimate
n/a
n/a
Pricing power
Moderate
Strong
Moat score
70 / 100
83 / 100
Moat domains
Supply, Legal, Demand
Demand, Supply
Last update
2026-06-03
2026-06-02

Moat coverage

Shared moat types

Data Workflow LockinSwitching Costs General

Elekta AB (publ) strengths

Capex Knowhow ScaleCompliance AdvantageProcurement InertiaInstalled Base ConsumablesService Field Network

Pro Medicus Limited strengths

Keystone ComponentOperational ExcellenceSuite BundlingLong Term Contracts

Segment mix

Elekta AB (publ) segments

Full profile >

Solutions

Oligopoly

55.8%

Service

Quasi-Monopoly

44.2%

Pro Medicus Limited segments

Full profile >

Visage 7 Enterprise Imaging Platform (PACS / CloudPACS)

Oligopoly

92.5%

Visage RIS (Radiology Information System) and Promedicus.net

Oligopoly

7.5%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Looking for expansion-stage stocks?

Proven models entering the expansion stage with unit economics that work.

View expansion-stage stocks

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.